Literature DB >> 184921

Histogenesis and Morphology of periosteal sarcomas induced by FBJ virus in NIH Swiss mice.

J M Ward, D M Young.   

Abstract

FBJ virus was injected i.p. into 145 neonatal NIH Swiss [N:NIH(s)] mice. Eighty mice developed a total of 110 neoplasms by 5 months of age. The mean latent period of the tumors was 71 days (26 to 145) postinjection. The frequency of occurrence of neoplasms at different sites was: diaphragm, 45%; ribs, 14%; vertebrae, 14%; femora, 9%; pelvic bones, 5%; tibiae, 4%; sternebrae, 3%; and inguinal area, 7%. The neoplasms were characterized histologically by elongated or rounded cells associated with an abundant connective tissue stroma. Occasional areas of bone formation and apparent osteoid metaplasia were seen. Bone tumors appeared to arise from periosteal cells, to grow by expansion, and to invade locally, but they failed to metastasize. Neoplasms of the diaphragm originated in the central aponeurosis and appeared histologically similar to bone neoplasms. Histochemical studies demonstrated abundant alkaline phosphatase in tumor cells, and ultrastructural observations revealed subcellular characteristics of osteoblasts and chondroblasts. Tumors were readily transplantable and had histopathological characteristics similar to those of the primary viral-induced tumors. The results of this study indicate that the FBJ virus induces in NIH Swiss mice a unique type of chondroosseous neoplasm derived from periosteal cells which has a resemblance to human juxtacortical (parosteal) osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184921

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  An avian transforming retrovirus isolated from a nephroblastoma that carries the fos gene as the oncogene.

Authors:  M Nishizawa; N Goto; S Kawai
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

Review 2.  Primary neoplasms of bones in mice: retrospective study and review of literature.

Authors:  A M Kavirayani; J P Sundberg; O Foreman
Journal:  Vet Pathol       Date:  2011-02-22       Impact factor: 2.221

Review 3.  Canine and murine models of osteosarcoma.

Authors:  Jessica Beck; Ling Ren; Shan Huang; Erika Berger; Kathleen Bardales; Joshua Mannheimer; Christina Mazcko; Amy LeBlanc
Journal:  Vet Pathol       Date:  2022-03-26       Impact factor: 3.157

4.  Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma.

Authors:  Virna D Leaner; Jeffrey F Chick; Howard Donninger; Ilona Linniola; Arnulfo Mendoza; Chand Khanna; Michael J Birrer
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

5.  FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA.

Authors:  T Curran; G Peters; C Van Beveren; N M Teich; I M Verma
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

6.  Human c-fos oncogene mapped within chromosomal region 14q21----q31.

Authors:  P E Barker; M Rabin; M Watson; W R Breg; F H Ruddle; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Differential expression of c-fos in hematopoietic cells: correlation with differentiation of monomyelocytic cells in vitro.

Authors:  R Müller; D Müller; L Guilbert
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

8.  c-fos expression precedes osteogenic differentiation of cartilage cells in vitro.

Authors:  E I Closs; A B Murray; J Schmidt; A Schön; V Erfle; P G Strauss
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

9.  Myristylation of FBR v-fos dictates the differentiation pathways in malignant osteosarcoma.

Authors:  R M Jotte; J T Holt
Journal:  J Cell Biol       Date:  1996-10       Impact factor: 10.539

10.  Osteoblasts are target cells for transformation in c-fos transgenic mice.

Authors:  A E Grigoriadis; K Schellander; Z Q Wang; E F Wagner
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.